Emerging therapies in chronic myeloid leukemia

Current Cancer Drug Targets

Volumn 12, Issue 5, 2012, Pages 458-470

  Gora Tybor, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aurora kinase inhibitors; Chronic myeloid leukemia; Leukemic stem cells; Ponatinib; Switch control inhibitors; Tyrosine kinase inhibitors

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 1 [3 TERT BUTYL 1 (6 QUINOLINYL) 1H PYRAZOL 5 YL] 3 [2 FLUORO 4 [[2 (METHYLCARBAMOYL) 4 PYRIDINYL]OXY]PHENYL]UREA; 17 ALLYLAMINOGELDAMYCIN; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BMS 833923; BOSUTINIB; DANUSERTIB; DASATINIB; FINGOLIMOD; GANETESPIB; GNF 1; GNF 2; HOMOHARRINGTONINE; HYDROXYCHLOROQUINE; IMATINIB; NILOTINIB; P 24534; PANOBINOSTAT; PF 04449913; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TOZASERTIB; UNCLASSIFIED DRUG; XL 228; ZILEUTON;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; AUTOPHAGY; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; EDEMA; EPIGENETICS; FATIGUE; FEVER; GENE MUTATION; HEADACHE; HUMAN; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREATITIS; PRURITUS; RASH; REVIEW; SIDE EFFECT; STEM CELL; THROMBOCYTOPENIA; VOMITING;

EID: 84861720878     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800673202     Document Type: Review

References (100)

1. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M. W.; Silver, R. T.; Goldman, J. M.; Stone, R. M.; Cervantes, F.; Hochhaus, A.; Powell, B. L.; Gabrilove, J. L.; Rousselot, P.; Reiffers, J.; Cornelissen, J. J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J. L.; Radich, J. P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R. A.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355, 2408-2417.
2. de Lavallade, H.; Apperley, J. F.; Khorashad, J. S.; Milojkovic, D.; Reid, A. G.; Bua, M.; Szydlo, R.; Olavarria, E.; Kaeda, J.; Goldman, J. M.; Marin, D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 2008, 26, 3358-3363.
3. Apperley, J. F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8, 1018.
4. Hochhaus, A.; Baccarani, M.; Deininger, M.; Apperley, J. F.; Lipton, J. H.; Goldberg, S.L.; Corm, S.; Shah, N. P.; Cervantes, F.; Silver, R. T.; Niederwieser, D.; Stone, R. M.; Dombret, H.; Larson, R. A.; Roy, L.; Hughes, T.; Müller, M. C.; Ezzeddine, R.; Countouriotis, A. M.; Kantarjian, H. M. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22, 1200-1206.
5. Kantarjian, H. M.; Giles, F.; Gattermann, N.; Bhalla, K.; Alimena, G.; Palandri, F.; Ossenkoppele, G. J.; Nicolini, F. E.; O'Brien, S. G.; Litzow, M.; Bhatia, R.; Cervantes, F.; Haque, A.; Shou, Y.; Resta, D. J.; Weitzman, A.; Hochhaus, A.; le Coutre, P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110, 3540-3546.
6. Keller, G.; Schafhausen, P.; Brummendorf, T. H. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev. Hematol. 2009, 2, 489-497.
7. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65, 4500-4505.
8. Apperley, J. F. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8, 1116-1128.
9. O'Hare, T.; Deininger, M. W.; Eide, C. A.; Clackson, T.; Druker, B. J. Targeting the BCR-ABL signaling pathway in therapyresistant Philadelphia chromosome-positive leukemia. Clin. Cancer Res. 2011, 15, 212-221.
10. Santos, F. P.; Quintás-Cardama, A. New drugs for chronic myelogenous leukemia. Curr. Hematol. Malig Rep. 2011, 6, 96-103.
11. O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W. S.; Xu, Q.; Metcalf, C. A. 3rd; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W.; Druker, B. J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16, 401-412.
12. Hochhaus, A.; O'Brien, S. G.; Guilhot, F.; Druker, B. J.; Branford, S.; Foroni, L.; Goldman, J. M.; Müller, M. C.; Radich, J. P.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T. P.; Larson, R. A. IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23, 1054-1061.
13. Quintás-Cardama, A.; Kantarjian, H.; Jones, D.; Shan, J.; Borthakur, G.; Thomas, D.; Kornblau, S.; O'Brien, S.; Cortes, J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high dose or standard-dose imatinib therapy. Blood 2009, 113, 6315-6321.
14. th Congress of the European Hematology Association, London, UK, June 9-12, 2011, 120-126.
15. Saglio, G.; Kim, D. W.; Issaragrisil, S.; Le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R. E.; Hochhaus, A.; Hughes, T. P.; Gallagher, N.; Hoenekopp, A.; Dong, M.; Haque, A, Larson, R. A.; Kantarjian, H. M. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362, 2251-2259.
16. Kantarjian, H.; Shah, N.; Cortes, J.; Baccarani, M.; Agarwal, M.; Undurraga, M.; Wang, J.; Ipiña, J.; Kim, D.; Ogura, M.; Pavlovsky, C.; Junghanss, C.; Milone, J.; Nicolini, F.; Robak, T.; Van Droogenbroeck, J.; Vellenga, E.; Bradley-Garelik, M.; Zhu, C.; Hochhaus, A. Dasatinib or imatinib in newly diagnosed chronicphase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012, 119, 1123-1129.
17. th Congress of the European Hematology Association, London, UK, June 9-12, 2011, 112-119.
18. Mahon, F. X.; Réa, D.; Guilhot, J.; Guilhot, F.; Huguet, F.; Nicolini, F.; Legros, L.; Charbonnier, A.; Guerci, A.; Varet, B.; Etienne, G.; Reiffers, J.; Rousselot, P. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11, 1029-1035.
19. Cortes, J. E.; Jones, D.; O'Brien, S.; Jabbour, E.; Konopleva, M.; Ferrajoli, A.; Kadia, T.; Borthakur, G.; Stigliano, D.; Shan, J.; Kantarjian, H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 2010, 28, 392-397.
20. Cortes, J. E.; Jones, D.; O'Brien, S.; Jabbour, E.; Ravandi, F.; Koller, C.; Borthakur, G.; Walker, B.; Zhao, W.; Shan, J.; Kantarjian, H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 2010, 28, 398-404.
21. O'Hare, T.; Corbin, A. S.; Druker, B. J. Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 2006, 16, 92.
22. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosée, P.; Müller, M.C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16, 2190.
23. Branford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Herrmann, R.; Seymour, J. F.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102, 276.
24. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2, 117.
25. Azam, M.; Latek, R. R.; Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112, 831.
26. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complexwith the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62, 4236.
27. Nardi, V.; Azam, M.; Daley, G. Q. Mechanisms and implications of imatinib resistancemutations in BCR-ABL. Curr. Opin. Hematol. 2004, 11, 35.
28. Huang, W. S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Luliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpipera zin-1-yl)methyl]-3-(trifluoromethyl) phenyl}benza-mide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem. 2010, 53, 4701-4719.
29. Zhou, T.; Commodore, L.; Huang, W. S.; Wang, Y.; Thomas, M.; Keats, J.; Xu, Q.; Rivera, V. M.; Shakespeare, W. C.; Clackson, T.; Dalgarno, D. C.; Zhu, X. Structural mechanism of the pan-BCRABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des. 2011, 77, 1-11.
30. Eide, C. A.; Adrian, L. T.; Tyner, J. W.; Mac Partlin, M.; Anderson, D. J.; Wise, S. C.; Smith, B. D.; Petillo, P. A.; Flynn, D. L.; Deininger, M. W.; O'Hare, T.; Druker, B. J. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011, 71, 3189-3195.
31. Marumoto, T.; Zhang, D.; Saya, H. Aurora-A-a guardian of poles. Nat. Rev. Cancer 2005, 5, 42-50.
32. Agnese, V.; Bazan, V.; Fiorentino, F. P.; Fanale, D.; Badalamenti, G.; Colucci, G.; Adamo, V.; Santini, D.; Russo, A. The role of Aurora-A inhibitors in cancer therapy. Ann. Oncol. 2007, 18, 47-52.
33. Gautschi, O.; Heighway, J.; Mack, P. C.; Purnell, P.R.; Lara, P. N. Jr.; Gandara, D. R. Aurora kinases as anticancer drug targets. Clin. Cancer Res. 2008, 14, 1639.
34. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10, 262-267.
35. Cheetham, G. M.; Charlton, P. A.; Golec, J. M.; Pollard, J. R. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 2007, 251, 323-329.
36. Young, M. A.; Shah, N. P.; Chao, L. H.; Seeliger, M.; Milanov, Z. V.; Biggs, W. H. 3rd; Treiber, D. K.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J.; Sawyers, C. L.; Kuriyan, J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006, 66, 1007-1014.
37. Gontarewicz, A.; Balabanov, S.; Keller, G.; Colombo, R.; Graziano, A.; Pesenti, E.; Benten, D.; Bokemeyer, C.; Fiedler, W.; Moll, J.; Brümmendorf, T. H. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008, 111, 4355-4364.
38. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinković, M.; Wyatt, P. G. Fragmentbased discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem. 2009, 52, 379-388.
39. Tanaka, R.; Squires, M. S.; Kimura, S.; Yokota, A.; Nagao, R.; Yamauchi, T.; Takeuchi, M.; Yao, H.; Reule, M.; Smyth, T.; Lyons, J. F.; Thompson, N. T.; Ashihara, E.; Ottmann, O. G.; Maekawa, T. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 2010, 116, 2089-2095.
40. Tang, R.; Faussat, A. M.; Majdak, P.; Marzac, C.; Dubrulle, S.; Marjanovic, Z.; Legrand, O.; Marie, J. P. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 downregulation in myeloid leukemiacells. Mol. Cancer Ther. 2006, 5, 723-731.
41. Berman, E. Omacetaxin: the FDA decision. Clin. Adv. Hematol. Oncol. 2011, 9, 57-58.
42. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
43. Grenert, J. P.; Sullivan, W. P.; Fadden, P.; Haystead, T. A.; Clark, J.; Mimnaugh, E.; Krutzsch, H.; Ochel, H. J.; Schulte, T. W.; Sausville, E.; Neckers, L. M.; Toft, D. O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 1997, 272, 23843-23850.
44. Blagosklonny, M. V.; Fojo, T.; Bhalla, K. N.; Kim, J. S.; Trepel, J. B.; Figg, W. D.; Rivera, Y.; Neckers, L. M. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001, 15, 1537-1543.
45. Nimmanapalli, R.; O'Bryan, E.; Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Ablpositive human leukemic blasts. Cancer Res. 2001, 61, 1799-1804.
46. Gorre, M.E.;Ellwood-Yen, K.; Chiosis, G.; Rosen, N.; Sawyers, C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100, 3041-3044.
47. Wang, Y.; Trepel, J. B.; Neckers, L. M.; Giaccone, G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr. Opin. Investig. Drugs 2010, 11,1466-1476.
48. Fabbro, D.; Manley, P. W.; Jahnke, W.; Liebetanz, J.; Szyttenholm, A.; Fendrich, G.; Strauss, A.; Zhang, J.; Gray, N. S.; Adrian, F.; Warmuth, M.; Pelle, X.; Grotzfeld, R.; Berst, F.; Marzinzik, A.; Cowan-Jacob, S. W.; Furet, P.; Mestan, J. Inhibitors of the Abl kinase directed at either the ATP-or myristate-binding site. Biochim. Biophys. Acta 2010, 1804, 454-462.
49. Adrián, F. J.; Ding, Q.; Sim, T.; Velentza, A.; Sloan, C.; Liu, Y.; Zhang, G.; Hur, W.; Ding, S.; Manley, P.; Mestan, J.; Fabbro, D.; Gray, N. S. Allosteric inhibitors of BCR-ABL dependent cell proliferation. Nature Chem. Biol.2006, 2, 95-102.
50. Zhang, J.; Adrián, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; Guo, G. R.; Ding, Q.; Okram, B.; Choi, Y.; Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P. W.; Engen, J. R.; Daley, G. Q.; Warmuth, M.; Gray, N. S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010, 463, 501-506.
51. Ross, D. M.; Branford, S.; Seymour, J. F.; Schwarer, A. P.; Arthur, C.; Bartley, P. A.; Slader, C.; Field, C.; Dang, P.; Filshie, R. J.; Mills, A. K.; Grigg, A. P.; Melo, J. V.; Hughes, T. P. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010, 24,1719-1724.
52. Sobrinho-Simoes, M.; Wilczek, V.; Score, J.; Cross, N. C.; Apperley, J. F.; Melo, J. V. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010, 116, 1329-1335.
53. Barnes, D. J.; Melo, J. V. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006, 5, 2862-2866.
54. Bhatia, R.; Holtz, M.; Niu, N.; Gray, R.; Snyder, D. S.; Sawyers, C. L.; Arber, D. A.; Slovak, M. L.; Forman, S. J. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101, 4701-4707.
55. Graham, S. M.; Jørgensen, H. G.; Allan, E.; Pearson, C.; Alcorn, M. J.; Richmond, L.; Holyoake, T. L. Primitive, quiescent, Philadelphiapositive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99, 319-325.
56. Jorgensen, H. G.; Allan, E. K.; Jordanides, N. E.; Mountford, J. C.; Holyoake, T. L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109, 4016-4019.
57. Copland, M.; Hamilton, A.; Elrick, L. J.; Baird, J. W.; Allan, E. K.; Jordanides, N.; Barow, M.; Mountford, J. C.; Holyoake, T. L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107, 4532-4539.
58. Corbin, A. S.; Agarwal, A.; Loriaux, M.; Cortes, J.; Deininger, M. W.; Druker, B. J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011, 121, 396-409.
59. Mizushima, N. Autophagy: process and function. Genes Dev. 2007, 21,2861-2873.
60. Liu, F, Guan, J. L. FIP200, an essential component of mammalian autophagy is indispensible for fetal hematopoiesis. Autophagy 2011, 7, 229-230.
61. Mortensen, M.; Soilleux, E. J.; Djordjevic, G.; Tripp, R.; Lutteropp, M.; Sadighi-Akha, E.; Stranks, A. J.; Glanville, J.; Knight, S.; Jacobsen, S. E.; Kranc, K. R.; Simon, A. K. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J. Exp. Med. 2011, 208, 455-467.
62. Helgason, G. V.; Karvela, M.; Holyoake T. L. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011, in press.
63. Rubinsztein, D. C.; Gestwicki, J. E.; Murphy, L. O.; Klionsky, D. J. Potential therapeutic applications of autophagy. Nat. Rev. Drug Discov. 2007, 6, 304-312.
64. Klejman, A.; Rushen, L.; Morrione, A.; Slupianek, A.; Skorski, T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene, 2002, 21, 5868-5876.
65. Mohi, M. G.; Boulton, C.; Gu, T. L.; Sternberg, D. W.; Neuberg, D.; Griffin, J. D.; Gilliland, D. G.; Neel, B. G. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA, 2004, 101, 3130-3135.
66. Carayol, N.; Vakana, E.; Sassano, A.; Kaur, S.; Goussetis, D. J.; Glaser, H.; Druker, B. J.; Donato, N. J.; Altman, J. K.; Barr, S.; Platanias, L. C. Critical roles for mTORC2-and rapamycininsensitive mTORC1-complexes in growth and survival of BCRABLexpressing leukemic cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 12469-12474.
67. Mishima, Y.; Terui, Y.; Mishima, Y.; Taniyama, A.; Kuniyoshi, R.; Takizawa, T.; Kimura, S.; Ozawa, K.; Hatake, K. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci. 2008, 99, 2200-2208.
68. Bellodi, C.; Lidonnici, M. R.; Hamilton, A.; Helgason, G. V.; Soliera, A. R.; Ronchetti, M.; Galavotti, S.; Young, K. W.; Selmi, T.; Yacobi, R.; Van Etten, R. A.; Donato, N.; Hunter, A.; Dinsdale, D.; Tirrò, E.; Vigneri, P.; Nicotera, P.; Dyer, M. J.; Holyoake, T.; Salomoni, P.; Calabretta, B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009, 119, 1109-1123.
69. Bernardi, R.; Pandolfi, P. P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Rev. Mol. Cell Biol. 2007, 8, 1006-1016.
70. Salomoni, P.; Pandolfi, P. P. The role of PML in tumor suppression. Cell 2002, 108, 165-170.
71. Wang, Z. G.; Ruggero, D.; Ronchetti, S.; Zhong, S.; Gaboli, M.; Rivi, R.; Pandolfi, P.P. PML is essential for multiple apoptotic pathways. Nature Genet. 1998, 20, 266-272.
72. Bernardi. R.; Guernah, I.; Jin, D.; Grisendi, S.; Alimonti, A.; Teruya-Feldstein, J.; Cordon-Cardo, C.; Simon, M. C.; Rafii, S.; Pandolfi P. P. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006, 442, 779-785.
73. Ito, K.; Bernardi, R.; Morotti, A.; Matsuoka, S.; Saglio, G.; Ikeda, Y.; Rosenblatt, J.; Avigan, D. E.; Teruya-Feldstein, J.; Pandolfi, P. P. PML targeting eradicates quiescent leukaemia initiating cells. Nature 2008, 453, 1072-1078.
74. Mathews, V.; George, B.; Lakshmi, K. M.; Viswabandya, A.; Bajel, A.; Balasubramanian, P.; Shaji, R. V.; Srivastava, V. M.; Srivastava, A.; Chandy, M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006, 107, 2627-2632.
75. Lallemand-Breitenbach, V.; Zhu, J.; Puvion, F.; Koken, M.; Honoré, N.; Doubeikovsky, A.; Duprez, E.; Pandolfi, P. P.; Puvion, E.; Freemont, P.; de Thé, H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 2001, 193, 1361-1371.
76. Chen, Y.; Peng, C.; Sullivan, C.; Li, D.; Li, S. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med. Chem. 2010, 10, 111-115.
77. Gupta, S.; Takebe, N.; Lorusso, P. Targeting the Hedgehog pathway in cancer. Ther. Adv. Med. Oncol. 2010, 2, 237-250.
78. Taipale, J.; Beachy, P. A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001, 17, 349-354.
79. Chen, J. K.; Taipale, J.; Cooper, M. K.; Beachy, P. A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002, 16, 2743-2748.
80. Zhao, C.; Chen, A.; Jamieson, C. H.; Fereshteh, M.; Abrahamsson, A.; Blum, J.; Kwon, H. Y.; Kim, J.; Chute, J. P.; Rizzieri, D.; Munchhof, M.; VanArsdale, T.; Beachy, P. A.; Reya, T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458, 776-779.
81. Dierks, C.; Beigi, R.; Guo, G. R.; Zirlik, K.; Stegert, M. R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008, 14, 238-249.
82. Janssens, V.; Goris, J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 2001, 353, 417-439.
83. Sontag, E. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal. 2001, 13, 7-16.
84. Janssens, V.; Goris, J.; Van Hoof, C. PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 2005, 15, 34-41.
85. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B. W.; Liu, S.; Mao, H.; Chang, J. S.; Galietta, A.; Uttam, A.; Roy, D. C.; Valtieri, M.; Bruner-Klisovic, R.; Caligiuri, M. A.; Bloomfield, C. D.; Marcucci, G.; Perrotti, D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL regulated SET protein. Cancer Cell. 2005, 8, 355-368.
86. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 2007, 117, 2408-2421.
87. Perrotti, D.; Neviani, P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br. J. Cancer 2006, 95, 775-781.
88. Matsuoka, Y.; Nagahara, Y.; Ikekita, M.; Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 2003, 138, 1303-1312.
89. Kahan, B. D. FTY720: from bench to bedside. Transplant. Proc. 2004, 36, 531S-543S.
90. Kovarik, J. M.; Schmouder, R.; Riviere, G. J.; Wang, Y.; Hunt, T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J. Clin. Pharmacol. 2004, 44, 532-537.
91. Virley, D. J. Developing therapeutics for the treatment of multiple sclerosis. Neuro Rx. 2005, 2, 638-649.
92. Werz, O.; Steinhilber, D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 2006, 112, 701-718.
93. Chen, Y.; Hu, Y.; Zhang, H.; Peng, C.; Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genetic 2009, 41,783-792.
94. Cress, W. D.; Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 2000, 184, 1-16.
95. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 3, 194-202.
96. Nimmanapalli, R.; Fuino, L.; Stobaugh, C.; Richon, V.; Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101, 3236-3239.
97. Fiskus, W.; Pranpat, M.; Bali, P.; Balasis, M.; Kumaraswamy, S.; Boyapalle, S.; Rocha, K.; Wu, J.; Giles, F.; Manley, P. W.; Atadja, P.; Bhalla, K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006, 108, 645-652.
98. Fiskus, W.; Pranpat, M.; Balasis, M.; Bali, P.; Estrella, V.; Kumaraswamy, S.; Rao, R.; Rocha, K.; Herger, B.; Lee, F.; Richon, V.; Bhalla, K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 2006, 12, 5869-5878.
99. Nimmanapalli, R.; Fuino, L.; Bali, P.; Gasparetto, M.; Glozak, M.; Tao, J.; Moscinski, L.; Smith, C.; Wu, J.; Jove, R.; Atadja, P.; Bhalla, K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003, 63, 5126-5135.
100. Zhang, B.; Strauss, A. C.; Chu, S.; Li, M.; Ho, Y.; Shiang, K. D.; Snyder, D. S.; Huettner, C. S.; Shultz, L.; Holyoake, T.; Bhatia, R. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010, 17, 427-442.